Gustavo Heresi-Davila
Medical Director, Pulmonary Vascular and CTEPH Programs · Cleveland Clinic Foundation
Credentials: · · · · ·
History
PresentPulmonary Vascular and CTEPH Programs · Cleveland Clinic Foundation
Research
Journal of the American College of Cardiology · 2005 · 286 citations
Causes and circumstances of death in pulmonary arterial hypertension
American Journal of Respiratory and Critical Care Medicine · 2013 · 207 citations
Impact of Multidisciplinary Pulmonary Embolism Response Team Availability on Management and Outcomes
The American Journal of Cardiology · 2019 · 123 citations
34 papers
20 papers
14 papers
10 papers
- JB
7 papers
- OM
7 papers
- MA
6 papers
5 papers
Grants
- 2024–2030
1/2 Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
National Heart, Lung, and Blood Institute · UH3
Contact PI · $1.7M · Cleveland Clinic Lerner Com-Cwru
- 2024–2025
1/2 Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
National Heart, Lung, and Blood Institute · UG3
Contact PI · $433.1K · Cleveland Clinic Lerner Com-Cwru
- 2014–2019
Insulin Resistance in Pulmonary Arterial Hypertension
National Heart, Lung, and Blood Institute · K23
Contact PI · $834.4K · Cleveland Clinic Lerner Com-Cwru
Clinical trials
- 2025–2030
Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
Principal investigator · Recruiting · Phase 2
Gustavo A Heresi, MD, MS
- 2017–2026
Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)
Principal investigator · Active not recruiting
The Cleveland Clinic